Combining resistance and pharmacology for optimum patient care

Current Opinion in HIV and AIDS

Volumn 2, Issue 3, 2007, Pages 157-168

  Khoo, Saye H ^a   Winston, Alan ^b   Back, David J ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Inhibitory quotients; Nonnucleoside reverse transcriptase inhibitors; Protease inhibitors; Therapeutic drug monitoring

Indexed keywords

AMPRENAVIR; ATAZANAVIR; DARUNAVIR; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LIPID; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SAQUINAVIR PLUS RITONAVIR; TIPRANAVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

AREA UNDER THE CURVE; CENTRAL NERVOUS SYSTEM; CLINICAL PRACTICE; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG MONITORING; FIRST TRIMESTER PREGNANCY; GASTROINTESTINAL TOXICITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; LIPODYSTROPHY; LIVER DISEASE; LIVER TOXICITY; MEDICAL DECISION MAKING; NEPHROTOXICITY; PATIENT CARE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PREGNANT WOMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME; URINARY TRACT DISEASE; VIRUS LOAD;

EID: 34250668398     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3280f31d27     Document Type: Review

References (89)

1. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347:385-394.
2. Pillay D. Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe. Antivir Ther 2004; 9:695-702.
3. Khoo SH, Gibbons SE, Back DJ. Therapeutic drug monitoring as a tool in treating HIV infection. AIDS 2001; 15 (Suppl 5):S171-S181.
4. Boffito M, Acosta E, Burger D, et al. Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy. Antivir Ther 2005; 10:375-392. Comprehensive review of TDM.
5. Khoo SH, Lloyd J, Dalton M, et al. Pharmacologic optimization of protease inhibitors and nonnucleoside reverse transcriptase inhibitors (POPIN): a randomized controlled trial of therapeutic drug monitoring and adherence support. J Acquir Immune Defic Syndr 2006; 41:461-467. RCT of TDM.
6. Dickinson L, Back D, Winston A, Khoo S, Boffito M. Intra-patient variability and comparison of saquinavir/ritonavir Ctrough concentrations between HIV-infected individuals and healthy volunteers administered saquinavir mesylate 500 mg film-coated tablets (1000/100 mg twice daily). In: 7th International Workshop on Clinical Pharmacology of HIV Therapy, 20-22 April 2006; Lisbon, Portugal.
7. Bossi P, Peytavin G, Ait-Mohand H, et al. GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy. HIV Med 2004; 5:352-359.
8. Burger D, Hugen P, Reiss P, et al. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS 2003; 17:1157-1165.
9. Clevenbergh P, Garraffo R, Durant J, Dellamonica P. PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results. AIDS 2002; 16:2311-2315.
10. Fletcher CV, Anderson PL, Kakuda TN, et al. Concentration- controlled compared with conventional antiretroviral therapy for HIV infection. AIDS 2002; 16:551-560.
11. Eron JJ, Feinberg J, Kessler HA, et al. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial. J Infect Dis 2004; 189:265-272.
12. Gibbons S, Dickinson L, Boffito M, et al. Is once-daily dosing of PIs associated with decreased tolerance for missed or late doses? In: 10th European AIDS Conference, November 2005; Dublin.
13. Nettles R, Kieffer T, Parsons T, et al. Frequent sampling in virologically suppressed patients taking HIV protease inhibitors or nonnucleoside reverse transcriptase inhibitors defines intra-individual pharmacokinetic variability. In: 12th Conference on Retroviruses and Opportunistic Infections, 22-25 February 2005; Boston.
14. Vrijens B, Urquhart J. Patient adherence to prescribed antimicrobial drug dosing regimens. J Antimicrob Chemother 2005; 55:616-627.
15. Veldkamp AI, Weverling GJ, Lange JM, et al. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS 2001; 15:1089-1095.
16. Veldkamp AI, van Heeswijk RPG, Mathot RAA, et al. Evaluation of exposure-response relationships for the nonnucleoside reverse transcriptase inhibitor (NNRTI) nevirapine in a cohort of HIV-infected individuals. In: 2nd International Workshop on Clinical Pharmacology of HIV Therapy, 2-4 April 2001; Noordwijk, The Netherlands.
17. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15:71-75.
18. Ribaudo HJ, Haas DW, Tierney C, et al. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis 2006; 42:401-407. Characterization of the role of pharmacogenetics in EFV clearance.
19. Leth FV, Kappelhoff BS, Johnson D, et al. Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy. AIDS Res Hum Retroviruses 2006; 22:232-239.
20. Burger D, Boyd M, Duncombe C, et al. Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. J Antimicrob Chemother 2003; 51:1231-1238.
21. Dieleman JP, Gyssens IC, van der Ende ME, et al. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS 1999; 13:473-478.
22. Merry C, Barry M, Gibbons S, et al. Improved tolerability of ritonavir derived from pharmacokinetic principles. Br J Clin Pharmacol 1996; 42:787.
23. Gathe JPD, Johnson M, Schwartz R, et al. Once-daily vs. twice-daily lopinavir/ritonavir in antiretroviral naive-patients: 48-week results [abstract]. 11th Conference on Retroviruses and Opportunistic Infections, 8-11 February 2004; San Francisco, CA, USA, Abstract 507.
24. Gonzalez de Requena D, Blanco F, Garcia-Benayas T, et al. Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir/ritonavir. AIDS Patient Care STDS 2003; 17:443-445.
25. Gonzalez de Requena D, Marrone R, Canta F, et al. Influence of atazanavir pharmacokinetics on both early virological response and bilirubin elevations. In: 5th International Workshop on Clinical Pharmacology of HIV Therapy, 11-13 March 2004; Rome, Italy.
26. Treluyer JM, Morini JP, Dimet J, et al. High concentrations of nelfinavir as an independent risk factor for lipodystrophy in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2002; 46:4009-4012.
27. Gutierrez F, Padilla S, Masia M, et al. Changes in body fat composition after 1 year of salvage therapy with lopinavir/ritonavir-containing regimens and its relationship with lopinavir plasma concentrations. Antivir Ther 2004; 9:105-113.
28. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004; 363:1253-1263.
29. Bergshoeff AS, Fraaij PL, van Rossum AM, et al. Pharmacokinetics of nelfinavir in children: influencing factors and dose implications. Antivir Ther 2003; 8:215-222.
30. Menson EN, Walker AS, Sharland M, et al. Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997-2005: cohort study. Bmj 2006; 332:1183-1187.
31. Verweel G, Sharland M, Lyall H, et al. Nevirapine use in HIV-1-infected children. AIDS 2003; 17:1639-1647.
32. Mirochnick M, Capparelli E. Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet 2004; 43:1071-1087.
33. Stek AM, Mirochnick M, Capparelli E, et al. Reduced lopinavir exposure during pregnancy. AIDS 2006; 20:1931-1939. Detailed study of lopinavir exposure in pregnancy.
34. Anderson PL, Kakuda TN, Kawle S, Fletcher CV. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. AIDS 2003; 17:2159-2168.
35. Rotger M, Csajka C, Telenti A. Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents. Curr HIV/AIDS Rep 2006; 3:118-125.
36. Kappelhoff BS, van Leth F, MacGregor TR, et al. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Antivir Ther 2005; 10:145-155.
37. Rotger M, Csajka C, Telenti A. Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents. Curr HIV/AIDS Rep 2006; 3:118-125.
38. Wyles DL, Gerber JG. Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction. Clin Infect Dis 2005; 40:174-181.
39. Best B, Witt M, Goicoechea M, et al. Improved antiretroviral exposure with therapeutic drug monitoring. In: 13th Conference on Retroviruses and Opportunistic Infections, 5-8 February 2006; Denver, USA.
40. Torti C, Quiros-Roldan E, Regazzi M, et al. A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study. Clin Infect Dis 2005; 40:1828-1836. RCT of TDM.
41. Castagna A, Gianotti N, Galli L, et al. The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects treated with a lopinavir/ritonavir-containing regimen. Antivir Ther 2004; 9:537-543.
42. Chantret M, Chapplain JM, Tribut O, et al. Is lopinavir genotypic inhibitory quotient (GIQ) a useful drug-monitoring tool in clinical practice? In: 9th European AIDS Conference (EACS), 1st EACS Resistance & Pharmacology Workshop, 25-29 October 2003; Warsaw, Poland.
43. Hellinger J, Morris AB, Piscitelli S, et al. Pilot study of saquinavir-SGC (Fortovase, SQV) 1000mg twice daily and lopinavir/ritonavir (Kaletra, LPV/r) in protease inhibitor-experienced HIV+ individuals: dose escalation andcombined normalized inhibitory quotient (cNIQ). In: 9th Conference on Retroviruses and Opportunistic Infections, 24-28 February 2002; Seattle, WA, USA.
44. Peytavin G, Delaguerre C, Dominguez S, et al. Pharmacological and virological factors associated with virological success in the GIGHAART study (ANRS907). In: 5th International Workshop on Clinical Pharmacology of HIV Therapy 2004; Rome, Italy.
45. Hoefnagel JG, Koopmans PP, Burger DM, et al. Role of the inhibitory quotient in HIV therapy. Antivir Ther 2005; 10:879-892. Comprehensive review of inhibitory quotients.
46. Bertz R, Li J, King M, et al. Lopinavir inhibitory quotient predicts virological response in highly antiretroviral-experienced patients receiving high-dose lopinavir/ritonavir. In: 11th Conference on Retroviruses and Opportunistic Infections, 8-11 February 2004; San Francisco, CA, USA.
47. Podzamczer D, Tressler R, Flexner C, et al. Higher doses of lopinavir/ritonavir (LPV/r) in highly treatment-experienced, HIV-infected patients: 48-week safety/efficacy evaluation. In: 15th International AIDS Conference, 11-16 July 2004; Bangkok, Thailand.
48. Hsu A, Isaacson J, Brun S, et al. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2003; 47:350-359.
49. Raguin G, Chene G, Morand-Joubert L, et al. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure. Antiviral Therapy 2004; 9:615-625.
50. Taburet AM, Raguin G, Le Tiec C, et al. Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus. Clin Pharmacol Ther 2004; 75:310-323.
51. Gonzalez de Requena D, Gallego O, Valer L, et al. Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient. AIDS Res Hum Retroviruses 2004; 20:275-278.
52. Breilh D, Pellegrin I, Rouzes A, et al. Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study). AIDS 2004; 18:1305-1310.
53. Cabie A, Lamotte C, Dos Santos G, et al. Therapeutic drug monitoring (TDM) of lopinavir/ritonavir (LPV/r) combination in Caribbean HIV infected patients. In: 15th International AIDS Conference, 11-16 July 2004; Bangkok, Thailand.
54. Marcelin AG, Cohen-Codar I, King MS, et al. Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients. Antimicrob Agents Chemother 2005; 49:1720-1726. One of the larger (n > 50) inhibitory quotient studies.
55. Torti C, Uccelli MC, Quiros-Roldan E, et al. Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naive for lopinavir with limited exposure to previous protease inhibitors. J Clin Virol 2006; 35:414-419. One of the larger (n > 50) inhibitory quotient studies.
56. Hoefnagel JG, van der Lee MJ, Koopmans PP, et al. The genotypic inhibitory quotient and the (cumulative) number of mutations predict the response to lopinavir therapy. AIDS 2006; 20:1069-1071. One of the larger (n > 50) inhibitory quotient studies.
57. Gianotti N, Galli L, Danise A, et al. Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir. J Med Virol 2006; 78:1537-1541.
58. Lam S, Delisle MS, Labbé L, et al. Genotypic inhibitory quotient as best pharmacokinetic/pharmacodynamic predictor of virological response to a lopinavir/saquinavir dual ritonavir-boosted regimen in patients with multiresistant HIV-1. In: 7th International Workshop on Clinical Pharmacology of HIV Therapy, 20-22 April 2006; Lisbon, Portugal.
59. Phillips E, Tseng A, Walker S, et al. The use of virtual inhibitory quotient (VIQ) in antiretroviral (ART)-experienced patients taking amprenavir/lopinavir combinations. In: 9th Conference on Retroviruses and Opportunistic Infections, 24-28 February 2002; Seattle, WA, USA.
60. Blanco JL, Mallollas J, Sarasa M, et al. Intensification therapy with lopinavir/ritonavir in heavily pretreated patients with virological failure 2002; XIV International AIDS Conference, Barcelona, Spain.
61. De Luca A, Baldini F, Cingolani A, et al. Deep salvage with amprenavir and lopinavir/ritonavir: correlation of pharmacokinetics and drug resistance with pharmacodynamics. J Acquir Immune Defic Syndr 2004; 35:359-366.
62. Duval X, Lamotte C, Race E, et al. Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir. Antimicrob Agents Chemother 2002; 46:570-574.
63. Barrail A, Droz C, Morand-Joubert L, et al. Calculation and predictivity of inhibitory quotients of amprenavir in heavily pretreated patients. In: 5th International Workshop on Clinical Pharmacology of HIV Therapy, 1-3 April 2004; Rome, Italy.
64. Marcelin AG, Lamotte C, Delaguerre C, et al. Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob Agents Chemother 2003; 47:594-600.
65. Marcelin AG, Delaguerre C, Ktorza N, et al. Genotypic and phenotypic inhibitory quotients as predictors of the virological response to a ritonavir/amprenavir containing regimen in HIV-1 protease inhibitor experienced patients. In: 7th International Congress on Drug Therapy in HIV Infection, 14-18 November 2004; Glasgow, Scotland.
66. Xu F, Tomkins S, Yates P, et al. Genotypic inhibitory quotient predicts response to fosamprenavir/ritonavir. In: 7th International Congress on Drug Therapy in HIV Infection, 14-18 November 2004; Glasgow, Scotland.
67. Clevenbergh P, Boulme R, Kirstetter M, Dellamonica P. Efficacy, safety and predictive factors of virological success of a boosted amprenavir-based salvage regimen in heavily antiretroviral-experienced HIV-1-infected patients. HIV Med 2004; 5:284-288.
68. Valer L, Gonzalez de Requena D, de Mendoza C, et al. Impact of drug levels and baseline genotype and phenotype on the virologic response to amprenavir/ritonavir-based salvage regimens. AIDS Patient Care STDS 2004; 18:1-6.
69. Fletcher CV, Jiang H, Brundage RC, et al. Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. J Infect Dis 2004; 189:1176-1184.
70. Casado JL, Moreno A, Sabido R, et al. Individualizing salvage regimens: the inhibitory quotient (Ctrough/IC50) as predictor of virological response. AIDS 2003; 17:262-264.
71. Marcelin AG, Dalban C, Peytavin G, et al. Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob Agents Chemother 2004; 48:4687-4692.
72. Valer L, de Mendoza C, Soriano V. Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients. J Med Virol 2005; 77:460-464. One of the larger (n > 50) inhibitory quotient studies.
73. Mallolas J, Blanco JL, Labarga P, et al. Inhibitory quotient (IQ) of saquinavir as prognostic factor of response to salvage antiretroviral therapy. In: 15th International AIDS Conference, 11-16 July 2004; Bangkok, Thailand.
74. Shulman N, Zolopa A, Havlir D, et al. Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia. Antimicrob Agents Chemother 2002; 46:3907-3916.
75. Barrios A, Rendon AL, Gallego O, et al. Predictors of virological response to atazanavir in protease inhibitor-experienced patients. HIV Clin Trials 2004; 5:201-205.
76. Gonzalez de Requena D, Bonora S, Canta FE, et al. Atazanavir Ctrough is associated with efficacy and safety: definition of therapeutic range. In: 12th Conference on Retroviruses and Opportunistic Infections, 22-25 February 2005; Boston, MA, USA.
77. Gianotti N, Seminari E, Guffanti M, et al. Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir. New Microbiol 2005; 28:119-125.
78. Pellegrin I, Breilh D, Ragnaud JM, et al. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study). Antivir Ther 2006; 11:421-429.
79. Valdez H, McCallister S, Hall DB, et al. Most highly treatment experienced tipranavir/ritonavir recipients achieve inhibitory quotients associated with large week 24 viral load reductions. In: Frontiers in Drug Development for Antiretroviral Therapies Meeting 2004; Montego Bay, Jamaica.
80. Mayers DL, Kohlbrenner VM, Dohnanyil C, et al. The inhibitory quotient (IQ) of tipranavir/ritonavir (TPV/r) in triple class experienced HIV+ patients: results from BI 1182.52. In: 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, 13-16 July 2003; Paris, France.
81. Naeger L, Zheng J, Struble K. Virologic response to tipranavir based on plasma concentration and baseline resistance parameters. In: 13th Conference on Retroviruses and Opportunistic Infections, 5-8 February 2006; Denver, CO, USA.
82. Bonora S, Gonzalez de Requena D, Calcagno A, et al. Tipranavir genotypic inhibitory quotient predicts early virological response at 24 weeks to TPV-based salvage regimens. In: 7th International Workshop on Clinical Pharmacology of HIV Therapy, 20-22 April 2006; Lisbon, Portugal.
83. Boffito M, Winston A, Fletcher CV, et al. Pharmacokinetics and ART response to TMC114/r and TMC125 combination in patients with high-level viral resistance. In: 13th Conference on Retroviruses and Opportunistic Infections, 5-8 February 2006; Denver, CO, USA.
84. Sekar V, De Meyer S, Vangeneugden T, et al. Absence of TMC114 exposure-efficacy and exposure-safety relationships in power 3. In: 16th International AIDS Conference, 13-18 August 2006; Toronto, Canada.
85. Baxter JD, Merigan TC, Wentworth DN, et al. Both baseline HIV-1 drug resistance and antiretroviral drug levels are associated with short-term virologic responses to salvage therapy. AIDS 2002; 16:1131-1138.
86. Winston A, Hales G, Amin J, et al. The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individuals. AIDS 2005; 19:1393-1399. One of the larger (n > 50) inhibitory quotient studies.
87. Winston A, Patel N, Back D, et al. Different methods to calculate the inhibitory quotient of boosted single protease inhibitors and their association with virological response. J Acquir Immune Defic Syndr 2006; 41:675-676.
88. Shulman N, Zolopa A, Havlir D, et al. Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia. Antimicrob Agents Chemother 2002; 46:3907-3916.
89. la Porte C, Back D, Blaschke TF, et al. Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. Rev Antiviral Ther 2006; 3:4-14.